Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

医学 因子IX 不利影响 队列 内科学 免疫系统 载体(分子生物学) 遗传增强 加药 免疫学 胃肠病学
作者
Lindsey A George,Paul E Monahan,M Elaine Eyster,Spencer K Sullivan,Margaret V Ragni,Stacy E Croteau,John E J Rasko,Michael Recht,Benjamin J Samelson-Jones,Amy MacDougall,Kristen Jaworski,Robert Noble,Marla Curran,Klaudia Kuranda,Federico Mingozzi,Tiffany Chang,Kathleen Z Reape,Xavier M Anguela,Katherine A High
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:385 (21): 1961-1973
标识
DOI:10.1056/nejmoa2104205
摘要

The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.In this phase 1-2 trial, we infused an investigational adeno-associated viral (AAV) vector (SPK-8011) for hepatocyte expression of factor VIII in 18 men with hemophilia A. Four dose cohorts were enrolled; the lowest-dose cohort received a dose of 5 × 1011 vector genomes (vg) per kilogram of body weight, and the highest-dose cohort received 2 × 1012 vg per kilogram. Some participants received glucocorticoids within 52 weeks after vector administration either to prevent or to treat a presumed AAV capsid immune response. Trial objectives included evaluation of the safety and preliminary efficacy of SPK-8011 and of the expression and durability of factor VIII.The median safety observation period was 36.6 months (range, 5.5 to 50.3). A total of 33 treatment-related adverse events occurred in 8 participants; 17 events were vector-related, including 1 serious adverse event, and 16 were glucocorticoid-related. Two participants lost all factor VIII expression because of an anti-AAV capsid cellular immune response that was not sensitive to immune suppression. In the remaining 16 participants, factor VIII expression was maintained; 12 of these participants were followed for more than 2 years, and a one-stage factor VIII assay showed no apparent decrease in factor VIII activity over time (mean [±SD] factor VIII activity, 12.9±6.9% of the normal value at 26 to 52 weeks when the participants were not receiving glucocorticoids vs. 12.0±7.1% of the normal value at >52 weeks after vector administration; 95% confidence interval [CI], -2.4 to 0.6 for the difference between matched pairs). The participants had a 91.5% reduction (95% CI, 88.8 to 94.1) in the annualized bleeding rate (median rate, 8.5 events per year [range, 0 to 43.0] before vector administration vs. 0.3 events per year [range, 0 to 6.5] after vector administration).Sustained factor VIII expression in 16 of 18 participants who received SPK-8011 permitted discontinuation of prophylaxis and a reduction in bleeding episodes. No major safety concerns were reported. (Funded by Spark Therapeutics and the National Heart, Lung, and Blood Institute; ClinicalTrials.gov numbers, NCT03003533 and NCT03432520.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
罗杰发布了新的文献求助10
刚刚
1秒前
hzs完成签到,获得积分10
1秒前
高大的剑身完成签到,获得积分10
1秒前
冉乐乐完成签到,获得积分10
1秒前
罗杰发布了新的文献求助10
2秒前
罗杰发布了新的文献求助10
2秒前
Carrie发布了新的文献求助10
2秒前
啦啦啦发布了新的文献求助10
2秒前
2秒前
平常夏山完成签到,获得积分10
2秒前
123完成签到,获得积分10
2秒前
2秒前
3秒前
yyyyy发布了新的文献求助10
3秒前
3秒前
3秒前
黄春松发布了新的文献求助10
4秒前
chenh89发布了新的文献求助10
4秒前
浩宁发布了新的文献求助10
4秒前
4秒前
科目三的应助被小低调采纳,获得10
4秒前
奔跑的应助被九耳久知采纳,获得60
4秒前
妮妮完成签到,获得积分10
5秒前
braver发布了新的文献求助10
5秒前
罗杰发布了新的文献求助10
5秒前
5秒前
蠹隙流光发布了新的文献求助10
5秒前
所所的应助被chen采纳,获得20
5秒前
小二郎的应助被haifeng采纳,获得10
6秒前
小蘑菇的应助被感动的易真采纳,获得10
6秒前
科研通AI6.4的应助被包bao采纳,获得10
6秒前
欣慰猕猴桃完成签到,获得积分10
6秒前
GGGGA发布了新的文献求助10
7秒前
妮妮发布了新的文献求助20
8秒前
清骨发布了新的文献求助10
8秒前
小红吃红薯完成签到,获得积分10
8秒前
风吹麦浪的应助被子时过采纳,获得10
8秒前
Cccsy发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157304
求助须知:如何正确求助?哪些是违规求助? 9553290
关于积分的说明 21713683
捐赠科研通 7746409
什么是DOI,文献DOI怎么找? 3426733
关于科研通互助平台的介绍 2551498
邀请新用户注册赠送积分活动 2470679